Joo-Hang Kim

CHA University Bundang Medical Center — South Korea

Medicine · Health Sciences

50h-index21.4kcitations251works7.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(142), Lung Cancer Research Studies(66), Lung Cancer Diagnosis and Treatment(45), Colorectal Cancer Treatments and Studies(36), Virus-based gene therapy research(35)

Publications247 total

Central Nervous System Outcomes of Lazertinib Treatment in EGFR-Mutated Advanced NSCLC: Pooled Analysis From LASER201 and LASER301
Clinical Lung Cancer·2025· 1 citedOpen Access
A phase 1b study of cofetuzumab pelidotin monotherapy in patients with PTK7-expressing recurrent non-small cell lung cancer
Lung Cancer·2025· 1 cited
Updated overall survival and ctDNA analysis in patients with EGFR T790M-positive advanced non-small cell lung cancer treated with lazertinib in the phase 1/2 LASER201 study
BMC Medicine·2024· 7 citedOpen Access
First-in-human study of ABBV-706, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors.
Journal of Clinical Oncology·2024· 21 cited
Lazertinib as a frontline treatment in patients with EGFR-mutated advanced non-small cell lung cancer: Long-term follow-up results from LASER201
Lung Cancer·2024· 8 citedOpen Access
Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-Mutated Advanced NSCLC: A LASER301 Subset Analysis
Journal of Thoracic Oncology·2023· 27 citedOpen Access
Lazertinib Versus Gefitinib Tyrosine Kinase Inhibitors in Treatment-Naíve Patients With EGFR-Mutated Advanced NSCLC: Analysis of the Asian Subpopulation in LASER301
Journal of Thoracic Oncology·2023· 15 citedOpen Access
Lazertinib versus Gefitinib as First-Line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset
Cancer Research and Treatment·2023· 5 citedOpen Access
Characterization of virus-mediated autoimmunity and the consequences for pathological process in patients with systemic lupus erythematosus
Clinical Rheumatology·2023· 4 cited
Supplementary Figure 4 from Glycolysis Inhibition Sensitizes Non–Small Cell Lung Cancer with T790M Mutation to Irreversible EGFR Inhibitors via Translational Suppression of Mcl-1 by AMPK Activation
2023Open Access
Data from Glycolysis Inhibition Sensitizes Non–Small Cell Lung Cancer with T790M Mutation to Irreversible EGFR Inhibitors via Translational Suppression of Mcl-1 by AMPK Activation
2023Open Access
Supplementary Figure 1 from Glycolysis Inhibition Sensitizes Non–Small Cell Lung Cancer with T790M Mutation to Irreversible EGFR Inhibitors via Translational Suppression of Mcl-1 by AMPK Activation
2023Open Access
Supplementary Figure Legends and Methods from Glycolysis Inhibition Sensitizes Non–Small Cell Lung Cancer with T790M Mutation to Irreversible EGFR Inhibitors via Translational Suppression of Mcl-1 by AMPK Activation
2023Open Access
Supplementary Figure 5 from Glycolysis Inhibition Sensitizes Non–Small Cell Lung Cancer with T790M Mutation to Irreversible EGFR Inhibitors via Translational Suppression of Mcl-1 by AMPK Activation
2023Open Access
Supplementary Figure 2 from Glycolysis Inhibition Sensitizes Non–Small Cell Lung Cancer with T790M Mutation to Irreversible EGFR Inhibitors via Translational Suppression of Mcl-1 by AMPK Activation
2023Open Access
Supplementary Figure 3 from Glycolysis Inhibition Sensitizes Non–Small Cell Lung Cancer with T790M Mutation to Irreversible EGFR Inhibitors via Translational Suppression of Mcl-1 by AMPK Activation
2023Open Access
Supplementary Figure 4 from Glycolysis Inhibition Sensitizes Non–Small Cell Lung Cancer with T790M Mutation to Irreversible EGFR Inhibitors via Translational Suppression of Mcl-1 by AMPK Activation
2023Open Access
Supplementary Figure 1 from Glycolysis Inhibition Sensitizes Non–Small Cell Lung Cancer with T790M Mutation to Irreversible EGFR Inhibitors via Translational Suppression of Mcl-1 by AMPK Activation
2023Open Access
Supplementary Figure Legends and Methods from Glycolysis Inhibition Sensitizes Non–Small Cell Lung Cancer with T790M Mutation to Irreversible EGFR Inhibitors via Translational Suppression of Mcl-1 by AMPK Activation
2023Open Access
Supplementary Figure 3 from Glycolysis Inhibition Sensitizes Non–Small Cell Lung Cancer with T790M Mutation to Irreversible EGFR Inhibitors via Translational Suppression of Mcl-1 by AMPK Activation
2023Open Access
page 1 of 13Next →

Frequent Co-authors

Byoung Chul Cho(16), Chae‐Ok Yun(13), Myung‐Ju Ahn(12), Keunchil Park(10), Hoguen Kim(9), Dong‐Wan Kim(8), Ji‐Youn Han(7), James Chih‐Hsin Yang(7), Eun Kyung Cho(6), Ki Hyeong Lee(6), Dae Ho Lee(6), Enriqueta Felip(5), Jong-Seok Lee(5), Young Joo Min(5), Dong‐Wan Kim(4), Sang-We Kim(4), Ross A. Soo(4), Sang‐We Kim(4), Hye Ryun Kim(4), Jin Hyoung Kang(4)